Overview
This prospective study aims to collect data and blood biomarkers from patients undergoing Lu-PSMA therapy at the Erasmus MC. In doing so, it will provide real-world efficacy and safety data on the drug, gather dosimetry data and explore putative biomarkers to identify patients who most benefit from Lu-PSMA treatment.
Eligibility
Inclusion Criteria:
- Participants should be at least 18 years old.
- Participants should be able to understand the written information and be able to provide informed consent.
- Participants are planned to start treatment with Lu-PSMA as a part of regular clinical care.
Exclusion Criteria:
None applicable